The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.
نویسندگان
چکیده
335 Address for correspondence: Prof. Piotr Kuna, MD, PhD, Department of Internal Medicine Asthma and Allergy Medical University of Lodz, ul. 22 Kopcinskiego 22, 90-153 Lodz, Poland, e-mail: [email protected] DOI: 10.5603/PiAP.2015.0053 Received: 13.06.2015 Copyright © 2015 PTChP ISSN 0867–7077 Zbigniew Bartuzi, Anna Bodzenta-Łukaszyk, Piotr Kuna, Izabela Kupryś-Lipińska, Ewa Niżankowska -Mogilnicka, Bolesław Samoliński Department of Allergology, Clinical Immunology and Internal Medicine Collegium Medicum University of Mikołaj Kopernik, Toruń, Poland Department of Allergology and Internal Medicine Medical in Białystok, Poland Department of Internal Medicine, Asthma and Allergy, University Hospital N. Barlicki, Łódź, Poland Pulmonology Clinic, Jagiellonian University, Collegium Medicum, Kraków, Poland Department of Prophylaxis of Environmental Threats and Allergology, Medical University in Warsaw, Poland
منابع مشابه
Omalizumab in the management of patients with allergic (IgE-mediated) asthma
Immunoglobulin E (IgE) is central to the pathophysiology of allergic asthma. Omalizumab, an anti-IgE monoclonal antibody, binds to the FcɛRI binding site on free IgE. As a result, circulating free IgE is reduced, IgE is prevented from attaching to mast cells and basophils, and FcɛRI receptor expression is down-regulated. The inflammatory response to allergens and the acute and chronic effector ...
متن کاملRecent Progress in Allergen Immunotherapy
The efficacy of allergen immunotherapy for the treatment of allergic rhinoconjunctivitis with or without seasonal bronchial asthma and anaphylaxis caused by the sting of the hymenoptera class of insects has been clearly demonstrated in numerous well-designed, placebo-controlled trials. Immunotherapy whether by subcutaneous injection of allergen extract or by oral/sublingual routes modifies peri...
متن کاملA review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma
Bronchial asthma is recognized as a highly prevalent health problem in the developed and developing world with significant social and economic consequences. Increased asthma severity is not only associated with enhanced recurrent hospitalization and mortality but also with higher social costs. The pathogenetic background of allergic-atopic bronchial asthma is characterized by airway inflammatio...
متن کاملTargeted therapy in severe asthma today: focus on immunoglobulin E
Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard "one size fits all" approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes,...
متن کاملOmalizumab: Clinical Use for the Management of Asthma
Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with moderate to severe allergic asthma whose asthma is poorly controlled with inhaled corticosteroids and inhaled long-acting β(2) agonist bronchodilators. This review considers the mechanism of action, pharmacokinetics, efficacy, safety and place in management of omalizumab in a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Pneumonologia i alergologia polska
دوره 83 4 شماره
صفحات -
تاریخ انتشار 2015